438185
Lovastatin
Lovastatin, CAS 75330-75-5, is an anti-hypercholesterolemic agent that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.
Synonyme(s) :
Lovastatin, Mevinolin, MK-803, L-Type Calcium Channel Blocker IV
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C24H36O5
Numéro CAS:
Poids moléculaire :
404.54
Numéro MDL:
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.77
Produits recommandés
Niveau de qualité
Pureté
≥95% (HPLC)
Forme
powder
Fabricant/nom de marque
Calbiochem®
Conditions de stockage
OK to freeze
protect from light
Couleur
white to off-white
Solubilité
ethanol: 25 mg/mL
DMSO: 50 mg/mL
Conditions d'expédition
ambient
Température de stockage
2-8°C
InChI
1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
Clé InChI
PCZOHLXUXFIOCF-BXMDZJJMSA-N
Description générale
An anti-hypercholesterolemic agent and an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase that blocks a series of biological events including: activation of p21ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes, farnesylation of p21ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin), and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase. Shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and block the transcription of the type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF. This product requires activation for use in cell synchronization studies and in cell-free assay systems for HMG-CoA studies.
An anti-hypercholesterolemic agent that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Has been shown to block a series of biological events including: the activation of p21ras by insulin in 3T3-L1 fibroblasts and 3T3-L1 adipocytes; the farnesylation of p21ras, which decreases the pool of intracellular Ras available for subsequent activation by growth factors (including insulin); and N-ras-induced neuronal differentiation. Causes cell cycle arrest in the late G1 phase through inhibition of proteasome. Has recently been shown to inhibit the stimulation of MAP kinase by insulin in HIRcB cells and to block the transcription of type-I SCR gene in THP-1-derived macrophages. Also blocks PDGF receptor tyrosine phosphorylation and MAP kinase activation by PDGF. This product requires activation for use in cell synchronization studies and in cell-free assay systems for HMG-CoA studies.
Actions biochimiques/physiologiques
Cell permeable: no
Primary Target
Activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
Activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
Product does not compete with ATP.
Reversible: no
Avertissement
Toxicity: Carcinogenic / Teratogenic (D)
Reconstitution
Following reconstitution aliquot, flush with an inert gas, and freeze (-20°C). Stock solutions, in high quality DMSO or ethanol are stable for up to 1 month at -20°C.
Autres remarques
Rao, S., et al. 1999. Proc. Natl. Acad. Sci. USA96, 7197.
Carel, K., et al. 1996. J. Biol. Chem.271, 30625.
McGuire, T.F., et al. 1996. J. Biol. Chem. 271, 27402.
Umetani, N., et al. 1996. Biochim. Biophys. Acta1303, 199.
Xu, X.Q., et al. 1996. Arch. Biochem. Biophys. 326, 233.
Reusch, J.E.-B., et al. 1995. J. Biol. Chem.270, 2036.
Jakobisiak, M., et al. 1991. Proc. Natl. Acad.Sci. USA88, 3628.
Keyomarsi, K., et al. 1991. Cancer Res.51, 3602.
Mendola, C.E., and Backer, J.M. 1990. Cell Growth Differ. 1, 499.
Carel, K., et al. 1996. J. Biol. Chem.271, 30625.
McGuire, T.F., et al. 1996. J. Biol. Chem. 271, 27402.
Umetani, N., et al. 1996. Biochim. Biophys. Acta1303, 199.
Xu, X.Q., et al. 1996. Arch. Biochem. Biophys. 326, 233.
Reusch, J.E.-B., et al. 1995. J. Biol. Chem.270, 2036.
Jakobisiak, M., et al. 1991. Proc. Natl. Acad.Sci. USA88, 3628.
Keyomarsi, K., et al. 1991. Cancer Res.51, 3602.
Mendola, C.E., and Backer, J.M. 1990. Cell Growth Differ. 1, 499.
Informations légales
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Mention d'avertissement
Warning
Mentions de danger
Conseils de prudence
Classification des risques
Carc. 2 - Repr. 2
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Martha M Monick et al.
Journal of immunology (Baltimore, Md. : 1950), 171(5), 2625-2630 (2003-08-21)
These studies demonstrate that treatment of macrophages with lovastatin, a cholesterol-lowering drug that blocks farnesylation and geranylgeranylation of target proteins, increases LPS-induced TNF-alpha production. This is reversed by the addition of mevalonate, which bypasses the lovastatin block. Examination of membrane
Marielle Cochet et al.
Veterinary research, 55(1), 32-32 (2024-03-17)
Outbreaks of West Nile virus (WNV) occur periodically, affecting both human and equine populations. There are no vaccines for humans, and those commercialised for horses do not have sufficient coverage. Specific antiviral treatments do not exist. Many drug discovery studies
Woo-Jin Lim et al.
Cells, 10(9) (2021-09-29)
Retrospective observational studies have reported that statins improve clinical outcomes in patients previously treated with programmed cell death protein 1 (PD-1)-targeting monoclonal antibodies for malignant pleural mesothelioma (MPM) and advanced non-small cell lung cancer (NSCLC). In multiple mouse cancer models
Cep57 and Cep57L1 maintain centriole engagement in interphase to ensure centriole duplication cycle.
Kei K Ito et al.
The Journal of cell biology, 220(3) (2021-01-26)
Centrioles duplicate in interphase only once per cell cycle. Newly formed centrioles remain associated with their mother centrioles. The two centrioles disengage at the end of mitosis, which licenses centriole duplication in the next cell cycle. Therefore, timely centriole disengagement
David W Sanders et al.
eLife, 10 (2021-04-24)
Many enveloped viruses induce multinucleated cells (syncytia), reflective of membrane fusion events caused by the same machinery that underlies viral entry. These syncytia are thought to facilitate replication and evasion of the host immune response. Here, we report that co-culture
Articles
Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique